Trials / Completed
CompletedNCT00092430
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,200 (planned)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Months – 23 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to demonstrate that an investigational refrigerated vaccine with measles, mumps, rubella, and varicella is well tolerated and has similar immune response when compared to a frozen vaccine with measles, mumps, rubella, and varicella.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks |
Timeline
- Start date
- 2002-09-26
- Primary completion
- 2003-06-09
- Completion
- 2003-06-09
- First posted
- 2004-09-27
- Last updated
- 2019-11-15
Source: ClinicalTrials.gov record NCT00092430. Inclusion in this directory is not an endorsement.